Li Yongwen, Liu Hongyu, Chen Jun
Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin 300052, China.
Zhongguo Fei Ai Za Zhi. 2014 Aug 20;17(8):625-34. doi: 10.3779/j.issn.1009-3419.2014.08.08.
C-MET is a coding product of proto oncogene c-MET, hepatocyte growth factor (HGF) receptor with tyrosine kinase activity. The abnormal expression of c-Met gene is correlated with the tumorigenesis and development of lung cancer. Once the tyrosine kinase is activated by the interaction between the HGF ligand and the TK receptor, and the activated kinase will promote the cell proliferation, angiogenesis, invasion and metastasis of different tumors, as well as lung cancer. The targeted therapy to HGF/c-Met signal pathway is a new highlight in the treatments of lung cancer. In this review, we will discuss the dysregulation of HGF/c-Met signal pathway in lung cancer and the new progress for the targeted drugs to this pathway.
C-MET是原癌基因c-MET的编码产物，是具有酪氨酸激酶活性的肝细胞生长因子（HGF）受体。c-Met基因的异常表达与肺癌的发生和发展相关。一旦酪氨酸激酶被HGF配体与TK受体之间的相互作用激活，激活的激酶将促进不同肿瘤包括肺癌的细胞增殖、血管生成、侵袭和转移。针对HGF/c-Met信号通路的靶向治疗是肺癌治疗的新亮点。在本综述中，我们将讨论肺癌中HGF/c-Met信号通路的失调以及针对该通路的靶向药物的新进展。
